C. Qi, Z. X. Obias, A. Scheetz, M. H. Malczynski, M. Warren et al., Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. 2006 Mars, J Clin Microbiol

F. C. Tenover, W. P. Stocker, S. Thompson, A. Clark, L. A. Limbago et al., Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci

. Sep, J Clin Microbiol

C. D. Doern, J. Y. , M. Gallegos, C. , D. Alspaugh et al.,

A. D. Burnham, Investigation of Linezolid Resistance in Staphylococci and Enterococci, J Clin Microbiol, 2016.

/. Tenover, W. P. Fc, S. Stocker, A. Thompson, L. A. Clark et al., Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci

. Sept, J Clin Microbiol

E. Bouza and P. Muñoz, Linezolid: pharmacokinetic characteristics and clinical studies, Clinical Microbiology and InfectionVolume, vol.7, pp.75-82, 2001.

T. L. Sisson, J. G. Hopkins, and N. K. , Age and sex effects on the pharmacokinetics of linezolid, Eur J Clin Pharmacol, 2002.

G. J. Conte, J. Kipps, and E. Zurlinden, Intrapulmonary pharmacokinetics of linezolid, Antimicrob Agents Chemother, 2002.

I. R. Welshman, S. T. Jungbluth, G. L. Stalker, D. J. Hopkins, and N. K. , Linezolid absolute bioavailability and the effect of food on oral bioavailability, Biopharm Drug Dispos, 2001.

J. G. Slatter, S. D. Feenstra, K. L. Welshman, I. R. Bruss, J. B. Sams et al.,

, Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of linezolid to healthy human subjects, Drug Metab Dispos, 2001.

M. E. Brier, S. D. Aronoff, G. R. Batts, D. H. Ryan, K. K. et al., Pharmacokinetics of linezolid in subjects with renal dysfunction, 2003.

. Sep, Antimicrob Agents Chemother

H. P. Al, Pharmacokinetics of linezolid in patients with liver disease, Antimicrob Agents Chemother, 1999.

G. E. Zurenko, Y. B. Schaadt, R. D. Allison, J. W. Kilburn, J. O. Glickman et al., In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, Antimicrob Agents Chemother, 1996.

M. A. , Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections, J Antimicrob Chemother, 2003.

D. Clemett and M. A. Linezolid, Drugs, 2000.

W. J. Munckhof, G. C. Turnidge, and J. D. , Post-antibiotic growth suppression of linezolid against Gram-positive bacteria, 2001.

M. J. Rybak, C. D. Moldovan, T. Aeschlimann, J. R. Kaatz, and G. W. , Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU 100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium, Antimicrob Agents Chemother, 1998.

M. T. Sweeney and Z. G. , In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected Gram-negative organisms, Antimicrob Agents Chemother, 2003.

G. P. Allen, C. R. Rybak, and M. J. , In vitro activities of quinupristindalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrugresistant staphylococci and enterococci in and in vitro pharmacodynamic model, Antimicrob Agents Chemother, 2002.

C. Jacqueline, N. D. Batard, and E. , In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2005.

C. Jacqueline, C. J. Grossi, and O. , In vitro and in vivo assessment of linezolid combined with ertapenem : a highly synergistic combination against methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2006.

P. Grohs, K. M. Gutmann, and L. , In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus, Antimicrob Agents Chemother, 2003.

K. Grif, D. M. Pfaller, K. Miglioli, P. A. Allerberger, and F. , In vitro activity of fosfomycin in combination with various antistaphylococcal substances, 2001.

C. Jacqueline, C. J. Le-mabecque, and V. , In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by timekill curve methods, J Antimicrob Chemother, 2003.

M. R. Barbachyn and F. C. , Oxazolidinone structure-activity relationships leading to linezolid, Angew Chem Int Ed Engl, 2003.

A. H. Lin, R. W. , T. J. Vidmar, and K. R. Marotti, The Oxazolidinone Eperezolid Binds to the 50S Ribosomal Subunit and Competes with Binding of Chloramphenicol and Lincomycin, Antimicrob Agents Chemother, 1997.

L. Dean, K. R. Shinabarger, W. Robert, A. H. Murray, P. Lin et al., Mechanism of Action of Oxazolidinones: Effects of Linezolid and Eperezolid on Translation Reactions, Antimicrob Agents Chemother, 1997.

P. Kloss, L. X. Dean, L. Shinabarger, and A. S. Mankin, Resistance Mutations in 23 S rRNA Identify the Site of Action of the Protein Synthesis Inhibitor Linezolid in the Ribosomal Peptidyl Transferase Center, J. Mol. Biol, 1999.

S. M. Swaney, M. C. Ganoza, and A. D. Shinabarger, The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria, Antimicrob Agents Chemother, 1998.

H. Aoki, L. K. Susan, M. Poppe, T. J. Poel, E. A. Weaver et al.,

C. Robert, D. L. Gadwood, M. C. Shinabarger, and . Ganoza, Oxazolidinone Antibiotics Target the P Site on Escherichia coli Ribosomes, 2002.

M. F. Leclercq, Activity of Linezolid against Gram-positive cocci possessing genes conferring resistance to proteins synthesis inhibitors, Journal of Antimicrobial Chemotherapy, 2000.

C. Gemmell, Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid, Journal of Antimicrobial Chemotherapy, 2002.

K. Bernardo, N. P. , S. Fleer, A. Schnaith, O. Utermohlen et al., Subinhibitory Concentrations of Linezolid Reduce Staphylococcus aureus Virulence Factor Expression, Antimicrob Agents Chemother, 2004.

E. Bouza and M. P. , Linezolid : pharmacokinetic characteristics and clinical studies

, Clin Microbiol Infect, 2001.

A. Marchese and S. G. , The oxazolidinones as a new family of antimicrobial agent, Clin Microbiol Infect, 2001.

T. R. Anderegg, S. H. Fritsche, T. R. Ross, J. E. Jones, and R. N. , Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program, 2005.

R. N. Jones, J. E. Thomas, R. Fritsche, and H. S. Sader, Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations, 2006.

A. Zahedi-bialvaei, M. R. , M. Yousefi, M. Asgharzadeh, and H. ,

. Kafil, Linezolid: a promising option in the treatment of Gram-positives, J Antimicrob Chemother, 2016.

K. D. Leuthner, C. C. Rybak, and M. J. , Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide nonsusceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

. Aug, J Antimicrob Chemother

F. Tubau, J. Linares, R. Martin, and F. Soriano, In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods, J Antimicrob Chemother, 2001.

E. Cercenado and E. Bouza, In vitro activity of linezolid against multiply resistant Grampositive clinical isolates, J Antimicrob Chemother, 2001.

C. Betriu and M. L. Palau, Comparative in vitro activities of linezolid, quinupristindalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible andresistant streptococci, Antimicrob Agents Chemother, 2000.

R. N. Jones and T. R. Anderegg, In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species, Diagn Microbiol Infect Dis, 2002.

E. Goldstein and C. V. Merriam, In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 Grampositive anaerobic and 31 Corynebacterium clinical isolates, Antimicrob Agents Chemother, 2003.

E. Goldstein and C. V. Merriam, Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Grampositive species, Actinomycetes, and Lactobacilli, Antimicrob Agents Chemother, 2005.

T. Schulin, M. J. Ferraro, M. Rc, and G. M. Eliopoulos, Susceptibilities of Legionella spp. to newer antimicrobials in vitro, Antimicrob Agents Chemother, 1998.

A. Gomez-flores and S. Said-fernandez, In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis, Antimicrob Agents Chemother, 2004.

F. Tubau, J. Linares, R. Martin, and F. Soriano, In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods, J Antimicrob Chemother, 2001.

G. E. Kenny and M. Susceptibilities-of-mycoplasma-hominis, Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones, Antimicrob Agents Chemother, 2001.

. Manninen, Linezolid (ZYVOX), the First Member of a Completely New Class of

, Antibacterial Agents for Treatment of Serious Gram-Positive Infections, J. Med. Chem, 2008.

C. Jacqueline and L. Perez, In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model, Antimicrob Agents Chemother, 2002.

M. P. Oramas-shirey and C. L. Dileto-fang, Efficacy of linezolid in a staphylococcal endocarditis rabbit model, J Antimicrob Chemother, 2001.

C. F. Dailey and L. V. Buchanan, Efficacy of linezolid i n treatment of experimental endocarditis caused by methicillinresistant Staphylococcus aureus, Antimicrob Agents Chemother, 2001.

D. W. Wareham, A. M. Karcher, and S. S. Das, Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid, J Infect, 2006.

E. Hill, M. C. Herregods, and W. Peetermans, Infective endocarditis treated with linezolid : case report and literature review, Eur J Clin Microbiol Infect Dis, 2006.

L. Alcala and C. Perez-fernandez-turegano, In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs, Antimicrob Agents Chemother, 2003.

J. Fortun and E. Navas, Linezolid for the treatment of multidrug-resistant tuberculosis, J Antimicrob Chemother, 2005.

J. C. Rodriguez, M. Lopez, and G. Royo, In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis, J Antimicrob Agents, 2002.

C. W. Ford and M. R. Barbachyn, The discovery of linezolid, the first oxazolidinone antibacterial agent, Curr Drug Targets Infect Disord, 2001.

I. Klare, C. Fleige, U. Geringer, A. Thurmer, J. Bender et al., Increased frequency of linezolid resistance among clinical Enterococcus faecium isolates from German hospital patients, J. Glob. Antimicrob. Resist, 2015.

R. E. Mendes, L. M. Deshpande, and R. N. Jones, Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms, Drug resistance Updates

M. A. Pfaller, R. E. Mendes, J. M. Streit, P. A. Hogan, and R. K. Flamm, ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries, J. Antimicrob. Chemother, 2017.

M. A. Pfaller, R. E. Mendes, J. M. Streit, P. A. Hogan, and R. K. Flamm, Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program, 2011.

S. Lee, D. Song, J. Hyang, K. S. Shim, and . Park,

, Korea: low rate of 23S rRNA mutations in Enterococcus faecium, 2017.

M. Lobritz, M. S. Rice, and L. B. , Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis, Antimicrob Agents Chemother, 2003.

S. H. Marshall, R. Hutton-thomas, R. A. Salata, and L. B. Rice, Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis, 2002.

N. Bourgeois-nicolaos, L. Massias, A. Andremont, and F. Doucet-populaire, Experimental dose regimen modelling of intestinal emergence of Enterococcus faecalis resistant to linezolid in gnotobiotic mice, 2006.

S. H. Marshall, D. C. Hutton-thomas, R. Salata, R. A. Rice, and L. B. , Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis, Antimicrob Agents Chemother, 2002.

J. B. Locke, H. M. Shaw, and K. J. , Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin, Antimicrob Agents Chemother, 2009.

H. Chen, W. Wu, M. Ni, Y. Liu, J. Zhang et al., Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms, J. Antimicrob. Agents, 2013.

C. A. Arias, V. M. Reyes, J. Panesso, D. Moreno, J. Castañeda et al., Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase, J Clin Microbiol, 2008.

T. L. Grove, L. J. Schwalm, E. L. Green, M. T. Booker, S. J. Silakov et al., A substrate radical intermediate in catalysis by the antibiotic resistance protein Cfr, Nat Chem Biol, 2013.

S. M. Toh, X. L. Arias, C. A. Villegas, M. V. Lolans, K. Quinn et al., Acquisition of a natural resistance gene renders a clinical strain of methicillinresistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, 2007.

M. Jun and . Microbiol,

K. S. Long, J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester, The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A, 2006.

J. K. Bender, C. Fleige, I. Klare, S. Fiedler, A. Mischnik et al., Detection of a cfr(B) variant in german Enterococcus faecium clinical isolates and the impact on linezolid resistance in Enterococcus spp, PLoS One, 2016.

Y. Liu, Y. Wang, S. Schwarz, S. Wang, L. Chen et al., Investigation of a multiresistance gene cfr that fails to mediate resistance to phenicols and oxazolidinones in Enterococcus faecalis, J. Antimicrob. Chemother, 2014.

Y. Wang, Y. Lv, J. Cai, S. Schwarz, L. Cui et al., A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin, J. Antimicrob. Chemother, 2015.

A. Brenciani, G. Morroni, C. Vincenzi, E. Manso, M. Mingoia et al., Detection in Italy of two clinical Enterococcus faecium isolates carrying both the oxazolidinone and phenicol resistance gene optrA and a silent multiresistance gene cfr, J. Antimicrob. Chemother, 2016.

L. K. Sharkey and A. O'neill, Antibiotic resistance ABC-F proteins: bringing target protection into the limelight, 2018.

R. Hua, M. D. Yun-xia, P. D. Wu, M. D. , M. Yang et al., Molecular Epidemiology and Mechanisms of 43 Low-Level Linezolid-Resistant Enterococcus faecalis Strains in, 2018.

A. Antonelli, M. M. D'andrea, A. Brenciani, C. L. Galeotti, G. Morroni et al., Characterization of poxtA, a novel phenicoloxazolidinone-tetracycline resistance gene from an MRSA of clinical origin, J. Antimicrob. Chemother, vol.81, 2018.

W. Ma, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard, CLSI (NCCLS), vol.26, pp.7-7, 2006.

F. D. Société and . Microbiologie, Détermination de la sensibilité aux antibiotiques

. Casfm/eucast, , p.6, 2018.

F. D. Société and . Microbiologie, Tableaux des concentrations critiques pour l'interprétation des CMI et des diamètres critiques des zones d'inhibition

. Casfm/eucast, , pp.70-77, 2018.

R. E. Mendes, L. M. David, J. Farrell, T. Spanu, G. Fadda et al., Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in, 2010.

H. S. Sotirios-tsiodras, G. Sakoulas, M. George, C. Eliopoulos, L. Wennersten et al., Linezolid resistance in a clinical isolate of Staphylococcus aureus, Lancet, 2001.

L. Diaz, P. Kiratisin, R. E. Mendes, D. Panesso, and V. Kavindra,

C. A. Singh and . Ariasa, Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis, Antimicrob Agents Chemother, 2012.

. Sadowy, Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance, Eur J Clin Microbiol Infect Dis, 2017.

C. F. , Nosocomial enterococci resistant to vancomycin--United States, 1989.

A. H. Mutnick, B. D. Turnidge, J. D. Jones, and R. N. , Spectrum and potency evaluation of a new oxazolidinone, linezolid : report from the SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis, 1998.

R. E. Mendes, P. A. Ronald, N. Jones, H. S. Sader, and R. K. Flamm, Surveillance for linezolid resistance via the Zyvox ® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates, Journal of Antimicrobial Chemotherapy, vol.71, issue.7, 2016.

, Centre National des Staphylocoques, Rapport annuel d'activité, 2017.

, Centre National des entérocoques, Rapport d'activité, 2018.